Scientists from the Fujisawa Pharmaceutical Company recently described the structure, relative stereochemistry, and pronounced cytotoxicity of WS9885B, a bacterial-derived natural product possessing an unprecedented hexacyclic architecture, a reactive bridgehead alkene, and 12 stereocenters. Against several cancer cell lines in vitro, WS9885B displays cytotoxicity as potent as paclitaxel (Taxol), an established drug for the treatment of ovarian and breast cancers. Like paclitaxel, WS9885B stabilizes cellular microtubules in vitro and warrants serious attention as a potential chemotherapeutic agent for the treatment of cancer. WS9885B combines the important elements of novel structure and high biological activity, and is thus an attractive objective for research in organic synthesis. This research proposal describes a hypothetical biogenesis and a novel strategy to achieve an enantioselective chemical synthesis of WS9885B from abundant and inexpensive starting materials. The proposed research seeks to challenge the hypothesis that the architecturally and stereochemically complex structure of WS9885B could evolve from a substantially less complex substance by spontaneous intramolecular reorganization. An enantioselective chemical synthesis of WS9885B would establish its absolute stereochemistry and permit a systematic study of the relationship between its constitution and microtubule-stabilizing properties and cytotoxicity. Long term goals of this research include: (1) to determine if the reactive bridgehead alkene of WS9885B causes covalent modification of microtubules or other cellular components; and (2) the employment of chemistry developed in the course of a total synthesis of WS9885B in syntheses of analogue structures in an effort to define a structure-activity profile for this fascinating cytotoxic natural product.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA085526-01
Application #
6086479
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Lees, Robert G
Project Start
2000-04-01
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
1
Fiscal Year
2000
Total Cost
$159,570
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Adam, Gregory C; Vanderwal, Christopher D; Sorensen, Erik J et al. (2003) (-)-FR182877 is a potent and selective inhibitor of carboxylesterase-1. Angew Chem Int Ed Engl 42:5480-4
Vanderwal, Christopher D; Vosburg, David A; Weiler, Sven et al. (2003) An enantioselective synthesis of FR182877 provides a chemical rationalization of its structure and affords multigram quantities of its direct precursor. J Am Chem Soc 125:5393-407
Sorensen, Erik J (2003) Architectural self-construction in nature and chemical synthesis. Bioorg Med Chem 11:3225-8
Vosburg, David A; Vanderwal, Christopher D; Sorensen, Erik J (2002) A synthesis of (+)-FR182877, featuring tandem transannular Diels-Alder reactions inspired by a postulated biogenesis. J Am Chem Soc 124:4552-3
Vanderwal, C D; Vosburg, D A; Sorensen, E J (2001) Intramolecular allenolate acylations in studies toward a synthesis of FR182877. Org Lett 3:4307-10